Opportunities for natural products in 21st century antibiotic discovery.

Natural products and their derivatives are mainstays of our antibiotic drugs, but they are increasingly in peril. The combination of widespread multidrug resistance in once susceptible bacterial pathogens, disenchantment with natural products as sources of new drugs, lack of success using synthetic compounds and target-based discovery methods, along with shifting economic and regulatory issues, conspire to move investment in research and development away from the antibiotics arena. The result is a growing crisis in antibiotic drug discovery that threatens modern medicine. 21st century natural product research is perfectly positioned to fill the antibiotic discovery gap and bring new drug candidates to the clinic. Innovations in genomics and techniques to explore new sources of antimicrobial chemical matter are revealing new chemistry. Increasing appreciation of the value of narrow-spectrum drugs and re-examination of once discarded chemical scaffolds coupled with synthetic biology methods to generate new compounds and improve yields offer new strategies to revitalize once moribund natural product programs. The increasing awareness that the combination of antibiotics with adjuvants, non-antibiotic compounds that overcome resistance and enhance drug activity, can rescue older chemical scaffolds, and concepts such as blocking pathogen virulence present orthogonal strategies to traditional antibiotics. In all these areas, natural products offer chemical matter, shaped by natural selection, that is privileged in this therapeutic area. Natural product research is poised to regain prominence in delivering new drugs to solve the antibiotic crisis.

[1]  Megan C. Garland,et al.  Chemical Strategies To Target Bacterial Virulence. , 2017, Chemical reviews.

[2]  C. Quave,et al.  Virulence Inhibitors from Brazilian Peppertree Block Quorum Sensing and Abate Dermonecrosis in Skin Infection Models , 2017, Scientific Reports.

[3]  Andrew C. Pawlowski,et al.  A Common Platform for Antibiotic Dereplication and Adjuvant Discovery. , 2017, Cell chemical biology.

[4]  A. Narechania,et al.  Transmission of Extensively Drug‐Resistant Tuberculosis in South Africa , 2017, The New England journal of medicine.

[5]  Randall Todd,et al.  Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella pneumoniae — Washoe County, Nevada, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[6]  Christopher J. Schwalen,et al.  A new genome-mining tool redefines the lasso peptide biosynthetic landscape , 2016, Nature chemical biology.

[7]  K. Ochi.  Insights into microbial cryptic gene activation and strain improvement: principle, application and technical aspects , 2016, The Journal of Antibiotics.

[8]  L. Silver.  A Gestalt approach to Gram-negative entry. , 2016, Bioorganic & medicinal chemistry.

[9]  T. Wencewicz.  New antibiotics from Nature's chemical inventory. , 2016, Bioorganic & medicinal chemistry.

[10]  Chad W. Johnston,et al.  Polyketide and nonribosomal peptide retro-biosynthesis and global gene cluster matching. , 2016, Nature chemical biology.

[11]  Gerard D. Wright.  Antibiotic Adjuvants: Rescuing Antibiotics from Resistance. , 2016, Trends in microbiology.

[12]  T. Roemer,et al.  Discovery of potent wall teichoic acid early stage inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[13]  Tilmann Weber,et al.  The evolution of genome mining in microbes - a review. , 2016, Natural product reports.

[14]  Z. Deng,et al.  Functional Genome Mining for Metabolites Encoded by Large Gene Clusters through Heterologous Expression of a Whole-Genome Bacterial Artificial Chromosome Library in Streptomyces spp , 2016, Applied and Environmental Microbiology.

[15]  J. O'Neill,et al.  Tackling drug-resistant infections globally: final report and recommendations , 2016 .

[16]  A. Gikas,et al.  Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call. , 2016, The Journal of antimicrobial chemotherapy.

[17]  M. Medema,et al.  Computational strategies for genome-based natural product discovery and engineering in fungi. , 2016, Fungal genetics and biology : FG & B.

[18]  Jonathan M Stokes,et al.  Cold Stress Makes Escherichia coli Susceptible to Glycopeptide Antibiotics by Altering Outer Membrane Integrity. , 2016, Cell chemical biology.

[19]  S. van Calenbergh,et al.  The Quorum Sensing Inhibitor Hamamelitannin Increases Antibiotic Susceptibility of Staphylococcus aureus Biofilms by Affecting Peptidoglycan Biosynthesis and eDNA Release , 2016, Scientific Reports.

[20]  E. Brown,et al.  Antibacterial drug discovery in the resistance era , 2016, Nature.

[21]  B. Moore,et al.  Identification of Thiotetronic Acid Antibiotic Biosynthetic Pathways by Target-directed Genome Mining. , 2015, ACS chemical biology.

[22]  G. Niu,et al.  Identification of novel mureidomycin analogues via rational activation of a cryptic gene cluster in Streptomyces roseosporus NRRL 15998 , 2015, Scientific Reports.

[23]  E. Brown,et al.  Unconventional screening approaches for antibiotic discovery , 2015, Annals of the New York Academy of Sciences.

[24]  Michael A Fischbach,et al.  Computational approaches to natural product discovery. , 2015, Nature chemical biology.

[25]  M. Cooper.  A community-based approach to new antibiotic discovery , 2015, Nature Reviews Drug Discovery.

[26]  A. Therien,et al.  Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. , 2015, Chemistry & biology.

[27]  K. Lewis,et al.  A new antibiotic kills pathogens without detectable resistance , 2015, Nature.

[28]  Gerard D. Wright,et al.  Opportunities for Synthetic Biology in Antibiotics: Expanding Glycopeptide Chemical Diversity , 2012, ACS synthetic biology.

[29]  S. Brady,et al.  Mining the metabiome: identifying novel natural products from microbial communities. , 2014, Chemistry & biology.

[30]  C. Verschoor,et al.  A macrophage-stimulating compound from a screen of microbial natural products , 2014, The Journal of Antibiotics.

[31]  Gerard D. Wright,et al.  An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria. , 2014, The Journal of antimicrobial chemotherapy.

[32]  N. Strynadka,et al.  Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance , 2014, Nature.

[33]  P. Dorrestein,et al.  Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A , 2014, Proceedings of the National Academy of Sciences.

[34]  E. Brown,et al.  Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation , 2013, Nature chemical biology.

[35]  Nicholas Waglechner,et al.  Identifying producers of antibacterial compounds by screening for antibiotic resistance , 2013, Nature Biotechnology.

[36]  Wendy R. Sanhai,et al.  A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. , 2013, The Lancet. Infectious diseases.

[37]  Pedro M. Pereira,et al.  Inhibition of WTA Synthesis Blocks the Cooperative Action of PBPs and Sensitizes MRSA to β-Lactams , 2012, ACS chemical biology.

[38]  S. Brady,et al.  Tetarimycin A, an MRSA-active antibiotic identified through induced expression of environmental DNA gene clusters. , 2012, Journal of the American Chemical Society.

[39]  J. Bérdy.  Thoughts and facts about antibiotics: Where we are now and where we are heading , 2012, The Journal of Antibiotics.

[40]  K. Lewis,et al.  Antibiotics: Recover the lost art of drug discovery , 2012, Nature.

[41]  Mike Tyers,et al.  Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. , 2011, Nature chemical biology.

[42]  M. Bibb,et al.  Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters , 2011, Microbial biotechnology.

[43]  A. Singh,et al.  Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. , 2011, ACS chemical biology.

[44]  D. Hughes,et al.  Induction of antimicrobial activities in heterologous streptomycetes using alleles of the Streptomyces coelicolor gene absA1 , 2010, The Journal of Antibiotics.

[45]  A. Bélanger,et al.  Use of Ichip for High-Throughput In Situ Cultivation of “Uncultivable” Microbial Species , 2010, Applied and Environmental Microbiology.

[46]  J. Davies,et al.  Origins and Evolution of Antibiotic Resistance , 1996, Microbiology and Molecular Biology Reviews.

[47]  T. Roemer,et al.  Isolation, structure elucidation, and biological activity of virgineone from Lachnum Wirgineum using the genome-wide Candida albicans fitness test. , 2009, Journal of natural products.

[48]  Yang Li,et al.  PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. , 2008, Chemistry & biology.

[49]  H. Moser,et al.  Physicochemical properties of antibacterial compounds: implications for drug discovery. , 2008, Journal of medicinal chemistry.

[50]  F. Ausubel,et al.  Prospects for plant-derived antibacterials , 2006, Nature Biotechnology.

[51]  Changsheng Zhang,et al.  Structural insight into the self-sacrifice mechanism of enediyne resistance. , 2006, ACS chemical biology.

[52]  Frederick M Ausubel,et al.  Identification of novel antimicrobials using a live-animal infection model , 2006, Proceedings of the National Academy of Sciences.

[53]  Jun Wang,et al.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.

[54]  V. Miao,et al.  Natural products to drugs: daptomycin and related lipopeptide antibiotics. , 2005, Natural product reports.

[55]  C. Gustafsson,et al.  Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Bignall.  Talking shop , 1912, The Lancet.